Development of therapeutic mRNA vaccines for chronic hepatitis B

Project: Research

Project Details


Chronic Hepatitis B Virus (HBV) infection impacts a quarter of a billion people worldwide and is the most common bloodborne infection and major cause of liver cancer in Australia. Although a preventive vaccine and antiviral therapies are widely available, chronic carriers of HBV rarely achieve a complete cure. Here, we will develop an HBV mRNA vaccine with proprietary immunogen and adjuvant design. In addition, the efficacy of the vaccine will be tested in mouse models. This project will lay the IP foundation for a novel vaccine which complements current therapies and will hopefully achieve a functional cure for chronic carriers.
Effective start/end date1/04/2211/09/23


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.